1	Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized
2	trial (the Cobovax study)
3	
4	Nancy H. L. Leung* <sup>#1,2</sup> , Samuel M. S. Cheng* <sup>1</sup> , Carolyn A. Cohen* <sup>3</sup> , Mario Martín-Sánchez <sup>1</sup> ,
5	Niki Y. M. Au <sup>1</sup> , Leo L. H. Luk <sup>1</sup> , Leo C. H. Tsang <sup>1</sup> , Kelvin K. H. Kwan <sup>1</sup> , Sara Chaothai <sup>1</sup> , Lison
6	W. C. Fung <sup>1</sup> , Alan W. L. Cheung <sup>3</sup> , Karl C. K. Chan <sup>1</sup> , John K. C. Li <sup>1</sup> , Yvonne Y. Ng <sup>1</sup> ,
7	Prathanporn Kaewpreedee <sup>3</sup> , Janice Z. Jia <sup>3</sup> , Dennis K. M. Ip <sup>1</sup> , Leo L. M. Poon <sup>1,3,4</sup> , Gabriel M.
8	Leung <sup>†1,2</sup> , J. S. Malik Peiris <sup>†1,3,4</sup> , Sophie A. Valkenburg <sup>†3,5</sup> , Benjamin J. Cowling <sup>†#1,2</sup>
9	
10	*Joint first authors with equal contribution
11	<sup>†</sup> Joint senior authors with equal contribution
12	<sup>#</sup> Corresponding authors
13	
14	Affiliations:
15	1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
16	Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
17	Special Administrative Region, China.
18	2. Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, New
19	Territories, Hong Kong Special Administrative Region, China.
20	3. HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The
21	University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
22	4. Centre for Immunology and Infection; Hong Kong Science and Technology Park, New
23	Territories, Hong Kong Special Administrative Region, China.

24	5. Department of Microbiology and Immunology, Peter Doherty Institute of Infection and
25	Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
26	
27	Clinicaltrials.gov registration: NCT05057169
28	
29	Running head: Crossover trial of CoronaVac and BNT162b2
30	Word count (abstract): 301
31	Word count (main text): 4,500
32	
33	Corresponding authors:
34	Benjamin Cowling, WHO Collaborating Centre for Infectious Disease Epidemiology and
35	Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong;
36	Hong Kong Special Administrative Region, China. <u>bcowling@hku.hk</u>
37	
38	Nancy Leung, WHO Collaborating Centre for Infectious Disease Epidemiology and Control,
39	School of Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong
40	Special Administrative Region, China. leungnan@hku.hk
41	
42	

# 44 ABSTRACT

45	Background: There are few trials comparing homologous and heterologous third doses of
46	COVID-19 vaccination with inactivated vaccines and mRNA vaccines.
47	<b>Methods:</b> We conducted an open-label randomized trial in adults >=18 years of age who
48	received two doses of inactivated vaccine (CoronaVac) or mRNA vaccine (BNT162b2) >=6
49	months earlier, randomised in 1:1 ratio to receive a third dose of either vaccine. We compared
50	the reactogenicity, immunogenicity and cell-mediated immune responses, and assessed vaccine
51	efficacy against infections during follow-up.
52	Results: We enrolled 219 adults who previously received two doses of CoronaVac and
53	randomised to CoronaVac ("CC-C", n=101) or BNT162b2 ("CC-B", n=118) third dose; and 232
54	adults who previously received BNT162b2 and randomised to CoronaVac ("BB-C", n=118) or
55	BNT162b2 ("BB-B", n=114). There were more frequent reports of mild reactions in recipients of
56	third-dose BNT162b2, which generally subsided within 7 days. Antibody responses against the
57	ancestral virus, Omicron BA.1 and BA.2 subvariant by surrogate neutralization and $PRNT_{50}$
58	were stronger for the recipients of a third dose of BNT162b2 over CoronaVac irrespective of
59	prior vaccine type. CD4 <sup>+</sup> T cells boost only occurred in CoronaVac-primed arms. We did not
60	identify differences in CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell responses between arms. When Omicron BA.2 was
61	circulating, we identified 58 infections with cumulative incidence of 15.3% and 15.4% in the
62	CC-C and CC-B (p=0.93), and 16.7% and 14.0% in the BB-C and BB-B arms, respectively
63	(p=0.56).
64	Conclusions: Similar levels of incidence of infection in each arm suggest all third dose
65	combinations may provide similar degrees of protection against prevalent Omicron BA.2

66 infection, despite very weak antibody responses to BA.2 in the recipients of a CoronaVac third

- 67 dose. Further research is warranted to identify appropriate correlates of protection for inactivated
- 68 COVID-19 vaccines.

### 70 INTRODUCTION

71 The accrual of population immunity to COVID-19 may ultimately allow communities to return 72 to normal, or at least to a "new-normal". Immunity can be acquired through surviving infections 73 or, preferably, by vaccination. An unprecedented global effort has led to the rapid development and deployment of COVID-19 vaccines.<sup>1</sup> Vaccines against COVID-19 have generally been 74 75 developed initially as either a single dose, or two doses of the same vaccine technology platform i.e. a homologous two-dose regimen.<sup>1</sup> The emergence of variants of concern (VOCs)<sup>2</sup> and 76 77 observed decrease in vaccine-induced immune responses within a few months after 78 vaccination<sup>3,4</sup> have led to the implementations of third dose ("booster") vaccination programs.<sup>5</sup> 79 While some booster campaigns have encouraged individuals to receive a homologous third dose, 80 a third/booster dose with a different vaccine platform, i.e., heterologous vaccination, could be 81 more feasible in some locations.<sup>6-8</sup> There is also a possibility that combining vaccine doses using 82 different vaccine platforms by heterologous prime-boost strategies might enhance the immune response.9 Heterologous vaccination has been investigated by a number of clinical trials with 83 mixed results depending on the initial platform and sequence of vaccination.<sup>7,10,11</sup> Conversely, 84 85 considerations over adverse events may prompt individuals to prefer one vaccine platform over the other.8 86

87

In Hong Kong, a subtropical city in southern China, the COVID-19 vaccination programme started in February 2021. The programme initially offered each adult in Hong Kong a choice of two doses of the inactivated whole-virion vaccine CoronaVac (Sinovac) 28 days apart, or two doses of mRNA vaccine BNT162b2 (BioNTech/Fosun Pharma, marketed by Pfizer outside China) 21 days apart, with broad eligibility criteria and availability. Subsequently, healthy adults

have been recommended to receive a third dose of either vaccine (i.e., allowing cross-over) as
soon as 90 days after the second dose.<sup>8</sup>

95

96 Safety, immunogenicity and efficacy are the main aspects evaluated before vaccines are licensed. There are few trials<sup>12</sup> comparing the potential advantages of homologous or heterologous third 97 98 doses in individuals who have previously received two doses of an inactivated vaccine or two 99 doses of an mRNA vaccine. Here, we conducted a randomized trial to compare the 100 immunogenicity and reactogenicity to BNT162b2 or CoronaVac in individuals that had 101 previously received two doses of those vaccines. In addition, in early 2022 during the biggest 102 local (fifth) wave the antigenically distinct Omicron BA.2 variant was the major circulating 103 strain,<sup>13</sup> which provided us an opportunity to evaluate the comparative efficacy of these different 104 vaccine combinations against infection.

105

### 106 METHODS

### 107 Trial design and participants

108 This study is an open-label randomized trial conducted in Hong Kong to measure the vaccine

109 (humoral) immunogenicity and reactogenicity of third doses with an mRNA vaccine

110 (BNT162b2) or an inactivated vaccine (CoronaVac) in adults who have previously received two

doses of either vaccine. BNT162b2 is a nucleoside-modified mRNA encoding the trimerized

112 SARS-CoV-2 spike glycoprotein formulated in lipid nanoparticles, and each 0.3mL dose

113 contains  $30\mu g$  of mRNA. CoronaVac is a Vero cell-based, aluminium hydroxide-adjuvanted,  $\beta$ -

propiolactone-inactivated vaccine, and each 0.5 ml dose includes 600SU of inactivated SARS-

115 CoV-2 virus.

116

117	Individuals were eligible for this study if they were Hong Kong residents, ≥18 years of age at
118	enrolment and had previously received a homologous two-dose primary series of either
119	BNT162b2 or CoronaVac, with the second dose received at least 6 months (180 days) earlier.
120	Exclusion criteria included: a history of confirmed SARS-CoV-2 infection, a delay of ≥43 days
121	between the first two vaccine doses, contraindication for COVID-19 vaccination such as severe
122	allergies, use of medication that could impair the immune system in the last 6 months (except
123	topical steroids or short-term oral steroids), use of immunoglobulins and/or any blood products
124	within 90 days prior to enrolment, and pregnant or nursing, or planning to become pregnant. The
125	study protocol (Clinicaltrials.gov NCT05057169) was approved by the Institutional Review
126	Board of the University of Hong Kong (ref: UW 21-492).

127

### 128 Randomization and masking

129 The random allocation process was concealed from both participants and the field investigation 130 team, by way of pre-assignment based on a computer-generated sequence of random numbers 131 administered by clicking a randomization button in the online data collection tool REDCap. 132 Participants received two-dose CoronaVac or BNT162b2 were randomised separately to receive 133 a third dose of either vaccine in a 1:1 ratio. We used a block randomization structure with block 134 sizes of 2, 4 and 6. The sequence of random numbers was generated prior to the start of the study 135 by a statistician using the computer software package R. For logistical reasons individuals were 136 randomized at the time vaccination appointments were made, and there were dropouts after 137 randomization and before vaccination. However, both the participants and field investigation 138 team were not aware of the intervention until after vaccination, as the vaccination was done by

139 separate unblinded nurses at the community vaccination centres. After vaccination, participants 140 were provided with vaccination cards as required by the local government indicating which 141 vaccine they had received, i.e. participants and field investigation team were also unblinded from 142 this time onwards. The staff conducting laboratory tests were blinded to the third dose allocation. 143 144 **Procedures** 145 Participants were enrolled from the general community (see Supplementary Information for 146 additional information on enrolment and follow-up). We collected 20ml blood samples 147 immediately prior to vaccination (Day 0) and scheduled follow-up blood draws at 28, 182 days 148 and 365 days after vaccination. In a voluntary subset of approximately 35% of participants we 149 collected additional 10ml whole blood samples at day 0, 7 and 28 for analysis of cell-mediated 150 immune responses (CMI). At each encounter for a blood draw we offered a HKD100 (USD13) 151 incentive in the form of a supermarket gift voucher. After vaccination, participants were provided with vaccination cards and tympanic thermometers, observed for 15-30 minutes for 152 153 immediate events, and then provided with an e-diary and requested to record daily on possible 154 (delayed) adverse events or symptoms for 7 days as well as any medical encounters. From March 155 2022, all participants were invited to participate in active surveillance to identify COVID-19 and 156 influenza virus infection using rapid antigen tests (RAT) at home every four days. We also 157 ascertained whether any participants had an infection identified by RAT or PCR after enrolment 158 but prior to the start of active surveillance. The active surveillance is continuing with information 159 collected up to May 31 included in the present analyses.

### 161 *Outcomes*

162	The primary outcome measure is the immunogenicity at 28 days after the third dose of either
163	BNT162b2 or CoronaVac, measured as geometric mean titer (GMT) of SARS-CoV-2 serum
164	neutralising antibodies using plaque reduction neutralization test (PRNT <sub>50</sub> ). The secondary
165	outcome measures included i) the geometric mean fold rise (MFR) of SARS-CoV-2 serum
166	neutralising antibody titers from baseline (Day 0) to Day 28, ii) magnitude and phenotype of
167	vaccine-specific IFN $\gamma^+$ CD4 <sup>+</sup> and IFN $\gamma^+$ CD8 <sup>+</sup> T-cell responses at Day 7 and 28, iii) the incidence
168	of solicited local and systemic adverse events, and iv) COVID-19 infections after receiving the
169	third vaccine dose.
170	

## 171 Sample size justification

172 For the primary outcome of vaccine immunogenicity, i.e. the GMT of SARS-CoV-2 serum 173 neutralising antibodies against the vaccine strain (ancestral virus) at 28 days after vaccination, a 174 sample size of 100 individuals in each study arm was chosen. Based on our preliminary data, 175 assuming  $\log_{10}(\text{GMT}(\text{PRNT}_{50} \text{ at Day } 0)) = \log_{10}(27) = 1.4$  with a standard deviation of 0.9, a 176 sample size of 80 individuals per group would provide 80% power to detect a difference in log<sub>10</sub> 177 GMT of 0.4 or greater at the 5% significance level. The same calculation applies in each stratum. 178 We aimed for at least 100 individuals in each study arm to allow for the possibility of withdrawal 179 from the study prior to the day 28 assessment.

180

### 181 Laboratory analysis

182 Blood samples were delivered to our study laboratory at the University of Hong Kong as soon as

possible, with the optimal delivery time within 24h. Clotted blood samples were stored in a

184	refrigerated container at 2-8°C immediately after collection and while in transit to the central
185	laboratory. Sera were extracted from the clotted blood samples within 48 hours after collection,
186	divided into 2-4 aliquots, and stored at -80°C until subsequent serologic testing. Heparinized
187	blood samples were kept at room temperature upon collection and while in transit and processed
188	within 24 hours of collection. Peripheral blood mononuclear cells (PBMCs) were isolated from
189	the heparinized (whole) blood using Ficoll-Paque and leucosep tubes, divided into 2 aliquots,
190	and cryopreserved in liquid nitrogen until further analysis for cell-mediated immune responses.
191	
192	Details of serologic testing, including our in-house enzyme-linked immunosorbent assay
193	(ELISA) for the receptor binding domain (RBD) of the spike protein, a surrogate virus
194	neutralisation test (sVNT) (GenScript) and a plaque reduction neutralisation test (PRNT), have
195	been described in our earlier study on the immunogenicity of third-dose BNT162b2 after two
196	doses of CoronaVac <sup>8</sup> . We aimed to test sera collected on Day 0 and 28 with ELISA against
197	ancestral virus and sVNT against both ancestral virus and Omicron variant in all participants,
198	and with PRNT against both ancestral virus and Omicron variant in a randomly selected subset
199	of 20 participants in each study arm. We have demonstrated a good correlation (r=0.77) between
200	PRNT <sub>50</sub> and sVNT neutralization percentage for ancestral virus in our earlier studies <sup>14</sup> . The
201	ELISA has a dynamic range of between 0 to 5, although it was not designed as a quantitative
202	assay. For ELISA a single 1:100 serum dilution and for sVNT a single 1:10 serum dilution was
203	tested respectively. For PRNT, a serial two-fold serum dilutions from 1:10 to 1:320 were tested
204	initially, and in participants with an initial PRNT <sub>50</sub> titer of $\geq$ 320, additional PRNT using a serial
205	two-fold serum dilutions from 1:40 to 1:1280 were performed. PRNT assays were carried out
206	using ancestral SARS-CoV-2 BetaCoV/Hong Kong/VM20001061/2020 (GISAID

.....

...

D 4 4 .....

207	EPI_ISL_412028) isolated in Vero-E6 cells (ATCC CRL-1586), the Pango lineage B.1.1.529
208	Omicron BA.1 subvariant designated hCoV-19/Hong Kong/VM21044713_WHP5047-S5/2021
209	(GISAID EPI_ISL_6716902) and BA.2 subvariant hCoV-19/Hong
210	Kong/VM22000135_HKUVOC0588P2/2022 (GISAID EPI_ISL_9570707) isolated in Vero-E6
211	TMRSS2 cells (Vero E6 cells overexpressing TMPRSS2, kindly provided by Dr S Matsuyama
212	and colleagues), <sup>15</sup> and the passage level 3 virus aliquots were used. Cells were maintained in
213	DMEM medium supplemented with 10% FBS and 100 U/ml penicillin-streptomycin (all from
214	ThermoFisher Scientific, Waltham, MA, USA). The PRNT <sub>50</sub> , PRNT <sub>80</sub> and PRNT <sub>90</sub> titers were
215	the highest serum dilutions neutralising $\geq$ 50%, $\geq$ 80% and $\geq$ 90% of input plaques, respectively.
216	The WHO control serum provided by the National Institute for Biological Standards and Control
217	20/136 gave PRNT <sub>50</sub> titers of 320 and 320 against the ancestral virus and 20 and 40 against the
218	Omicron variant in two titrations.

219

-----

......

. .

220 The cell-mediated immune responses to the third dose COVID-19 vaccination, proxy by the 221 cytokine production of IFNy (in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells) or IL4 (in CD4<sup>+</sup> T cells only) of T 222 cells, were assessed in a randomly-selected subset of 20 participants in each study arm by 223 intracellular cytokine staining (ICS). All testing was done in two experiments with each 224 experiment including 10 participants randomly selected from each study arm, and time point 225 samples collected from the same participant tested in parallel in the same experiment. Samples 226 with a positive value after subtracting the respective value of the DMSO control were classified 227 as having a positive response ("responder") (value of DMSO control for CD4<sup>+</sup> IFN $\gamma^+$  T cells: 228 0.001%; CD8<sup>+</sup> IFNγ<sup>+</sup> T cells: 0.00017%; CD4<sup>+</sup> IL4<sup>+</sup> T cells: 0.000039%). Furthermore, CD4<sup>+</sup> 229 and CD8<sup>+</sup> T cell memory phenotypes (CD45RA/CD27) and cytokine polyfunctional quality

230	(TNF $\alpha$ /IL2) were assessed by gating on IFN $\gamma^+$ cells for samples which were classified as CD4 <sup>+</sup>
231	IFN $\gamma^+$ T cell or CD8 <sup>+</sup> IFN $\gamma^+$ T cell responders <sup>16</sup> . Cryopreserved PBMCs collected on Day 0, 7
232	and 28 were thawed and re-stimulated with an overlapping peptide pool representing the SARS-
233	CoV-2 structural proteins (spike, nucleocapsid, envelope and membrane) (300nM) or DMSO
234	(1% in RPMI) in two independent experiments. Cells were stimulated for a total of 28 hours at
235	37°C. Golgi Plug (BD) containing Brefeldin A (1% in PBS), and Golgi Stop (BD) containing
236	Monensin (0.67% in PBS) was added at 24 hours during stimulation for further 4-hour
237	incubation. The amino acid sequence of the peptide pools was based on $\beta$ CoV/Hong
238	Kong/VM20001061/2020 strain (GISAID ID: EPI_ISL_412028). Cells were stained with
239	Zombie-NIR (all antibodies from Biolegend and clone used) followed by anti-human CD3-
240	PE/Dazzle 594 (UCHT1), CD4-BV605 (OKT4), CD8-AlexaFluor700 (SK1), CCR7-
241	PerCP/Cy5.5 (G043H7), PD-1-BV421 (NAT105), CD45RA-APC (HI100), and a dump channel
242	containing CD19-BV510 (HIB19), CD56-BV510 (5.1H11) and CD14-BV510 (M5E2).
243	Following cell permeabilization, intracellular staining with anti-IFN <sub>γ</sub> -FITC (4S.B3), IL4-PE
244	(MP4-25D2) and TNFα-BV711 (Mab11), IL2-PECy7 (MQ1-17H12), was carried out before
245	acquisition of samples. Stained cells were acquired via flow cytometry (AttuneNxT) and
246	analysed by FlowJo v10. All samples met the cell viability cut-off of at least 30% and thus have
247	been included in the analyses.

248

## 249 Statistical analysis

We included all available data on participants who received a third dose of vaccination in our
trial. For post-vaccination reactions, solicited local and systemic events or symptoms were
presented as frequency (%) among participants who reported health status for ≥7 days in the

253	week following receipt of the third dose. We compared the proportions of the participants with
254	adverse events between the two study arms in individuals who had a prior recipient of two-dose
255	BNT162b2, or who had a prior recipient of two doses of CoronaVac, using the Chi-squared test
256	or Fisher's exact test. Severity score as a proxy of interference to usual activities was calculated
257	by assigning 0-reactions absent, 1-mild, 2-moderate and 3-severe and taking the average over the

258 week after vaccination, and compared between groups using Student's t-tests.

259

260 For antibody responses, for sVNT measured negative neutralization percentages were 261 transformed to zero. PRNT titers were taken as the reciprocal of the serum dilution and were 262 interval-censored, e.g. a sample that was able to neutralise virus at a 1:20 dilution but not at a 263 1:40 dilution was reported as 20 to indicate that the titer was  $\geq$ 20 and  $\leq$ 40. We estimated the 264 arithmetic mean of SARS-CoV-2 surrogate virus neutralization percentages and concentrations 265 of SARS-CoV-2 Spike RBD IgG (proxy by OD<sub>450</sub>) on Day 28. For PRNT titers, we imputed 266 titers <10 with the value 5 and titers  $\geq$ 1280 with the value 2560, and then transformed to  $\log_2$ 267 scale for the estimation of GMT and MFR, and significant testing. We compared antibody levels 268 between Day 0 and Day 28 using Wilcoxon signed rank tests. We compared antibody levels at 269 Day 28 between study arms using Mann-Whitney U tests. For cell-mediated response, we 270 transformed CD4<sup>+</sup> IFN $\gamma^+$  T cell, CD8<sup>+</sup> IFN $\gamma^+$  T cell and CD4<sup>+</sup> IL4<sup>+</sup> T cell responses to log10 271 scale for the estimation of geometric means and fold-rises and significance testing. CD4<sup>+</sup> and 272 CD8<sup>+</sup> T cell memory phenotypes and cytokine polyfunctional quality were assumed zeros for 273  $CD4^{+}/CD8^{+}$  IFN $\gamma^{+}$  T cell non-responders. We compared T cell responses between Day 0 and 274 Day 7, and between Day 0 and Day 28, using Wilcoxon signed rank tests. We compared T cell 275 responses at Day 7, and at Day 28, between study arms using Mann-Whitney U tests.

$\sim$	$\overline{}$	1
		n
_	/	U.

277	We compared the cumulative incidence of infections in each study arm using Kaplan-Meier
278	curves and compared the incidence of infections using proportional hazards model. The
279	proportional hazards model was specified on a calendar time axis with follow up starting from
280	the start of Hong Kong's fifth wave on 1 January 2022 or on the date of third dose if later, and
281	ending at the earliest of the time of infection, the time of receiving a fourth dose, the time of
282	withdrawing from the study, or the censoring date on 31 May 2022. If a participant reported
283	more than one instance of positive result by RAT or PCR, the earliest date of identification was
284	considered the time of infection. All statistical analyses were conducted using R version 4.2.1 (R
285	Foundation for Statistical Computing, Vienna, Austria).
286	
287	RESULTS
288	From 12 November 2021 through 27 January 2022, we screened 994 individuals and 818 (82%)
289	passed the initial eligibility assessment (Figure 1, Figure S1). We randomized 364 individuals
290	to the CC-C (178) and CC-B (186) arms, and 406 individuals to the BB-C (202) and BB-B (204)
291	arms. After final confirmation of eligibility, we collected baseline (Day 0) blood samples from
292	451 participants and then administered third doses, including 101 (57%) CC-C participants, 118
293	(63%) CC-B participants, 118 (58%) BB-C participants, and 114 (56%) BB-B participants.
294	Participant characteristics were generally comparable between the CC-C and CC-B arms, and
295	between the BB-C and BB-B arms (Table 1). Participants in the CC-C arm (median aged 58
296	years, IQR 50-64) were slightly older than those in CC-B (52 years, 43-58) ( $p = 0.01$ ). For all
297	451 vaccinated participants, most reported receiving the second dose 6-8 months earlier (Table

- A subset of 156 (35%) participants agreed to provide PBMCs samples on Day 0, 7 and Day
   28 to evaluate cell-mediated immune responses ("CMI group").
- 300

301	We collected information on post-vaccination reactions in 424 (94%) participants, including 193
302	(64%) who reported ever feeling unwell after vaccination, with significantly more frequent
303	reactions in recipients of a third dose of BNT162b2 that mostly subsided within 7 days (Figure
304	<b>2</b> , <b>Table S3</b> ). Fever ≥38.0°C was reported by about 10% of participants in both BB-B and CC-B
305	arms, but by none in BB-C and CC-C arms (Table S3). Among 440 participants who reported
306	information on medical care and hospitalisation, 10 reported seeking ambulatory care within one
307	month of the third dose, including 4 (1 in CC-C and 3 in CC-B) for discomfort associated with
308	vaccination (Table S4). One BB-B participant reported hospitalisation within a month of
309	vaccination for unrelated reasons (Table S4).
310	

311 Third-dose vaccination significantly increased neutralising antibodies, measured as sVNT 312 inhibition percentage or PRNT<sub>50</sub> titers, against the ancestral virus, Omicron BA.1 and BA.2 on 313 Day 28 from baseline in all four study arms regardless of third dose vaccine type (Figure 3, 314 **Table S5**). In particular, third-dose vaccination increased PRNT<sub>50</sub> titers against ancestral virus 315 by 14-, 94-, 3- and 19-folds, and against Omicron BA.2 by 1-, 16-, 1- and 13-folds, in CC-C, 316 CC-B, BB-C and BB-B arms respectively (Figure S2A). In both assays, antibody responses to a 317 BNT162b2 third dose were substantially and statistically significantly greater than responses to a 318 CoronaVac third dose regardless of prior two-dose vaccine type (Figure 3, Figure S2A, Table 319 S5). Similar significant differences between study arms were observed when comparing binding 320 antibodies against ancestral virus by ELISA (Figure S3, Table S6), or when comparing

neutralizing antibodies evaluated at higher neutralization inhibition thresholds (PRNT<sub>80</sub> or
PRNT<sub>90</sub> titers) (Figure S4, Table S6).

323

324	In a subset of 20 participants randomly selected from each study arm (Table S2), we found that
325	vaccination significantly increased the number of IFN $\gamma^+$ CD4 $^+$ T cells (indicative of a Th1
326	response) in both CC-C and CC-B arms on Day 7, which remained significantly elevated from
327	Day 0 on Day 28 (Figure 4A, Figure S2B). There was no significant change in IFN $\gamma^+$ CD4 <sup>+</sup> T
328	cells in both BB-C and BB-B arms on both Day 7 and Day 28 (Figure 4A, Figure S2B).
329	Separately, 30-50% participants in all arms had IFN $\gamma^+$ CD8 <sup>+</sup> T cells (indicative of a CTL
330	response) at baseline, but these were only significantly boosted in CC-B arm on Day 7 and
331	contracted by Day 28 (Figure 4B, Figure S2B). Meanwhile, IL4 <sup>+</sup> CD4 <sup>+</sup> T cells (indicative of a
332	Th2 response) were not significantly boosted by third doses in any arm (Figure S2B, Figure
333	<b>S5</b> ). There were no significant differences in the magnitude of CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell responses
334	between third doses of CoronaVac or BNT162b2 (Table S6, Table S7). We also evaluated the
335	multi-cytokine production (TNF $\alpha$ and IL-2) and memory phenotype of IFN $\gamma$ -producing CD4 <sup>+</sup> or
336	CD8 <sup>+</sup> T cells. We observed a bias towards single cytokine responses (IFN $\gamma^+$ ) as the majority of
337	the T cell responses, but expansions upon vaccination of double cytokine responses (IFN $\gamma^+$ with
338	$TNF\alpha^+$ or IL-2 <sup>+</sup> ) in CC-C and CC-B; and T effector memory responses predominated across all
339	arms and were further expanded in CC-C and CC-B (Figure 4C and 4D, Table S5).
340	
341	We identified 58 SARS-CoV-2 infections by 31 May 2022, within 4-6 months of receipt of the
342	third dose of vaccination. During this period the Omicron BA.2 variant was locally circulating.

343 The number of infections identified by arm was 13/85 (15.3%) in CC-C, 16/104 (15.4%) in CC-

344	B, 16/96 (16.7%) in BB-C and 13/93 (14.0%) in BB-B arms, with no statistically significant
345	difference detected between the CC-C and CC-B arms ( $p = 0.93$ ) nor between the BB-C and BB-
346	B arms ( $p = 0.56$ ) (Figure 5). Comparing BB-B and BB-C groups, the hazard ratio for a
347	BNT162b2 third dose compared to a CoronaVac third dose was 0.80 (95% confidence interval:
348	0.39, 1.67) corresponding to a relative vaccine efficacy of 20%, while the hazard ratio for CC-B
349	versus CC-C was 0.97 (95% confidence interval: 0.47, 2.01) corresponding to a relative vaccine
350	efficacy of 3%. Additional information on active surveillance is available in Supplementary
351	Materials.
352	
353	DISCUSSION
354	Here, we have conducted a comprehensive assessment of the reactogenicity, antibody response,
355	T cell responses and risk of infection in a randomised trial of homologous and heterologous
356	boosting with BNT162b2 and CoronaVac. Our population had minimal COVID-19 infection
357	history prior to all three doses of vaccination, <sup>17</sup> and absence of known prior COVID-19 infection
358	was one of the inclusion criteria. Furthermore, SARS-CoV-2 infection attack rate in the
359	population of Hong Kong assessed by population based sero-surveillance studies was
360	approximately 1% prior to the fifth wave of infections (unpublished data), thus likelihood of
361	unsuspected infection in this cohort prior to vaccination was low. When evaluating the ability to
362	boost immune response by a third vaccine dose, we showed that regardless of the combinations,
363	a third vaccine dose increased neutralising antibody against all ancestral virus, the Omicron
364	BA.1 and BA.2 variants significantly from baseline (Figure 3). The phenotype of the T cell
365	responses was predominantly effector memory and single cytokine producing across all vaccine
366	arms, but CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell responses were only boosted in CC-C and CC-B, and no

367	differences were found between all arms in total magnitude of T cell responses, phenotype or
368	proportion responders (Figure 4). Prior influenza research has suggested the differentiation state
369	of T cell responses can impact recall potential at infection and protection from disease. <sup>18</sup> Thus,
370	mRNA vaccine as a booster substantially increased antibody response, and those primed with
371	two-dose inactivated vaccines by receiving mRNA or inactivated vaccine booster will benefit the
372	T cell response, each providing an immunological layer against COVID-19. These findings
373	suggest there is immune benefit of administering either a homologous or heterologous third dose
374	six months after the second dose, especially more prominent in adults who initially received two
375	doses of an inactivated vaccine.
376	
377	The humoral and cellular immune results taken together would be indicative of superior efficacy
378	of a third dose of BNT162b2 but that is not what we observed (Figure 5). Rates of infection,
379	with Omicron BA.2 predominant in the community, were very similar among study arms
380	(Figure 5). This discrepancy may indicate the challenge of using neutralising antibody as a
381	correlate or mediator of protection against infection, <sup>19,20</sup> at least in comparisons between
382	vaccination strategies of mRNA and inactivated vaccines. Although neutralizing antibody did
383	appear to be a correlate of protection when comparing RNA and adenovirus vectored vaccines
384	and in comparisons between vaccinated and unvaccinated individuals, <sup>21-23</sup> antibody alone may
385	not explain the protection provided by inactivated vaccines, especially against viruses such as
386	Omicron which have high escape from neutralizing antibody elicited by ancestral virus. T-cell
387	responses may also play a role, as well as potentially non-neutralizing antibodies to internal virus
388	genes such as the nucleocapsid. A discordance between neutralizing antibody titres and vaccine

effectiveness against severe disease was also noted by us previously.<sup>24</sup> Such differences between
vaccine types may not always have been accounted for in immunobridging studies<sup>25</sup>.

392	The CD4 <sup>+</sup> helper T cell response, which has been shown to confer heterologous protection
393	against lung damage from infection by Beta variant in mice, <sup>26</sup> was significantly boosted and
394	maintained by both homologous (CC-C) and heterologous (CC-B) third dose after two doses of
395	inactivated vaccine (Figure 4). This is consistent with earlier findings, <sup>27,28</sup> and these studies
396	additionally suggested cross-reactivity against the Omicron variant by a third dose. Conversely,
397	there was no boost of T cell responses neither by a homologous nor heterologous third dose after
398	two doses of BNT162b2 (Figure 4), however a high level of responders at baseline was observed
399	in both arms (Figure 4A and 4B). The CD8 <sup>+</sup> cytotoxic T cell response, which may have a role in
400	limiting COVID-19 disease severity, <sup>29,30</sup> was significantly boosted at Day 7 although not
401	maintained to memory (Day 28) by heterologous third-dose BNT162b2 after two doses of
402	CoronaVac (Figure 4). While the initial two doses were not randomized and participants did
403	differ in a number of ways (Table S9), more participants who previously received two-dose
404	BNT162b2 (80-90% responders) had CD4+ T cell responses compared to those who previously
405	received two-dose CoronaVac (60-70% responders), and similar proportions of participants had
406	CD8 <sup>+</sup> T cell response at baseline between all arms (30-50% responders, Figure 4). In addition,
407	the baseline CD4 <sup>+</sup> T cell response of participants who received prior two doses of BNT162b2
408	were similar to the levels after third-dose vaccination in participants received prior two doses of
409	CoronaVac (Figure 4). These may suggest a ceiling effect on the T cell response among
410	participants who previously received two doses of BNT162b2 and explain the lack of boost in

411 cell-mediated immunity in the BB-C and BB-B arms, which has also been observed
412 elsewhere.<sup>28,31</sup>

413

414 Our study has several limitations. First, due to logistical challenges, we were only able to 415 randomise at the time vaccination appointment was made but not at vaccination, and nearly half 416 of randomized individuals dropped out before vaccination. However, the rates of dropout were 417 similar across study arms, and we have taken great care in the randomisation and allocation 418 concealment so that individuals dropping out were not aware of their allocated vaccine type. 419 Comparisons between study arms did not identify significant differences in most baseline 420 characteristics measured, except vaccinated participants in CC-B were on average 6 years 421 younger than those in CC-C, and vaccinated participants in BB-B were over twice more likely to 422 have hypertension than those in BB-C (Table 1). We also did not observe any significant 423 differences in all antibody and cell-mediated response measured at baseline (Table S6). Second, 424 in our study we did not include an unvaccinated control group, nor a two-dose comparison 425 group, to evaluate the additional benefits of third dose over existing two doses. Third, we have 426 only studied neutralising antibodies and T cell response, while other branches of immunity such as non-neutralising antibodies<sup>32,33</sup> may also contribute to protection and may explain the 427 428 discrepancy in our immunologic and efficacy data. Finally, our study population consists of 429 adults whom first immune priming was from either mRNA or inactivated vaccination, which is 430 different to many parts of the world where the first immune priming was from natural infection. This might lead to differences in subsequent immune response,<sup>34</sup> vaccine effectiveness<sup>35</sup> and 431 duration of protection,<sup>36</sup> and our study findings should be interpreted with these considerations. 432 433

434	In conclusion, our results suggest there is immune benefit in both administering a homologous or
435	heterologous third dose 6 months after two doses of inactivated or mRNA vaccination, with
436	similar levels of protection against infection provided by all four combinations. Mass vaccination
437	programmes that offer both inactivated and mRNA vaccines, with explanation on their potential
438	advantages and disadvantages, will help individuals in deciding their preferred option, allow
439	flexibility in vaccine deployment, and encourage vaccine uptake. <sup>37</sup> Our finding that neutralizing
440	antibody may not be the dominant correlate of protection for inactivated vaccines, especially
441	against SARS-CoV-2 variants such as Omicron that have significant capacity to evade
442	neutralizing antibody, needs to be considered in the development of "variant proof" COVID-19
443	vaccines or vaccines broadly protective against sarbecoviruses currently in development. <sup>38</sup>
444	

### 446 **REFERENCES**

- 1. Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development:
- 448 milestones, lessons, and prospects. Immunity 2021;54:1636-51.
- 449 2. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-
- 450 2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
- 451 Lancet 2021;397:2461-2.
- 452 3. Cowling BJ, Wong IOL, Shiu EYC, et al. Strength and durability of antibody responses
- 453 to BNT162b2 and CoronaVac. Vaccine 2022;40:4312-7.

454 4. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose
455 of BNT162b2 or ChAdOx1. Lancet 2021;398:385-7.

- 456 5. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster
  457 against Covid-19 in Israel. N Engl J Med 2021;385:1393-400.
- 458 6. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of

459 heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-

460 adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority

461 trial. Lancet 2022;399:36-49.

462 7. Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19

463 vaccine schedules—To mix or not to mix? The Lancet Infectious Diseases 2022;22:438-40.

464 8. Leung NHL, Cheng SMS, Martin-Sanchez M, et al. Immunogenicity of a third dose of

465 BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of

466 inactivated vaccine. Clin Infect Dis 2022.

467 9. Dangi T, Class J, Palacio N, Richner JM, Penaloza MacMaster P. Combining spike- and
468 nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep 2021;36:109664.

Atmar RL, Lyke KE, Deming ME, et al. Homologous and Heterologous Covid-19

469

10.

470	Booster Vaccinations. N Engl J Med 2022;386:1046-57.
471	11. Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous
472	COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19
473	vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet
474	2022;399:521-9.
475	12. Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19
476	vaccine schedules—To mix or not to mix? Lancet Infect Dis 2022;22:438-40.
477	13. Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-CoV-2
478	Omicron BA.2 Variant, Hong Kong, January-March 2022. Emerg Infect Dis 2022;28.
479	14. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing
480	antibody responses after infection and estimates of the duration of protection. EClinicalMedicine
481	2021;41:101174.
482	15. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by
483	TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 2020;117:7001-3.
484	16. Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of
485	BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 2022;27:301-10.
486	17. Chen LL, Abdullah SMU, Chan WM, et al. Contribution of low population immunity to
487	the severe Omicron BA.2 outbreak in Hong Kong. Nat Commun 2022;13:3618.
488	18. Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection
489	against symptomatic pandemic influenza. Nat Med 2013;19:1305-12.
490	19. Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2
491	infection and COVID-19 disease. Immunol Rev 2022.

- 492 20. Lim WW, Leung NHL, Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Distinguishing
- 493 Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop
- 494 Influenza Vaccines. Am J Epidemiol 2020;189:185-92.
- 495 21. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
- 496 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med
- 497 2021;27:1205-11.
- 498 22. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the
- 499 mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:43-50.
- 500 23. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
- asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032-40.
- 502 24. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three
- 503 doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based
- 504 observational study. The Lancet Infectious Diseases 2022.
- 505 25. ICMRA COVID-19 Vaccine development: Future steps Workshop. 2021. (Accessed
- 506 August 9, 2022, 2022, at <u>https://www.icmra.info/drupal/en/covid-19/24june2021</u>.)
- 507 26. Kingstad-Bakke B, Lee W, Chandrasekar SS, et al. Vaccine-induced systemic and
- 508 mucosal T cell immunity to SARS-CoV-2 viral variants. Proc Natl Acad Sci U S A
- 509 2022;119:e2118312119.
- 510 27. Chen Y, Chen L, Yin S, et al. The Third dose of CoronVac vaccination induces broad and
- 511 potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
- 512 Emerg Microbes Infect 2022;11:1524-36.
- 513 28. Jung MK, Jeong SD, Noh JY, et al. BNT162b2-induced memory T cells respond to the
- 514 Omicron variant with preserved polyfunctionality. Nat Microbiol 2022;7:909-17.

515	29.	Kedzierska K.	Thomas PG.	Count on us: '	T cells in	SARS-CoV-2	2 infection and
~ + ~					1 44110 111		

- 516 vaccination. Cell Rep Med 2022;3:100562.
- 517 30. Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol 2022;23:186518 93.
- 519 31. Romero-Olmedo AJ, Schulz AR, Hochstätter S, et al. Dynamics of humoral and T-cell
- 520 immunity after three BNT162b2 vaccinations in adults older than 80 years. The Lancet
- 521 Infectious Diseases 2022;22:588-9.
- 522 32. Bartsch YC, Tong X, Kang J, et al. Omicron variant Spike-specific antibody binding and
- 523 Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci Transl
- 524 Med 2022;14:eabn9243.
- 525 33. López-Muñoz AD, Kosik I, Holly J, Yewdell JW. Cell surface SARS-CoV-2
- 526 nucleocapsid protein modulates innate and adaptive immunity. Science Advances 2022;8.
- 527 34. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2
- 528 infection leads to robust humoral response and antibodies that effectively neutralize variants.
- 529 Science Immunology 2022;7.
- 530 35. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and
- 531 Vaccination on Symptomatic Omicron Infections. N Engl J Med 2022;387:21-34.
- 532 36. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19
- 533 Vaccination and Previous Infection. N Engl J Med 2022;386:1207-20.
- 534 37. Sprengholz P, Eitze S, Korn L, Siegers R, Betsch C. The power of choice: Experimental
- 535 evidence that freedom to choose a vaccine against COVID-19 improves willingness to be
- vaccinated. Eur J Intern Med 2021;87:106-8.

- 537 38. Morens DM, Taubenberger JK, Fauci AS. Universal Coronavirus Vaccines An Urgent
- 538 Need. N Engl J Med 2022;386:297-9.

539

# 541 Acknowledgements

542	We gratefully acknowledge colleagues including Teresa So, Justin Wan and Eileen Yu for
543	technical support in preparing and conducting this study; Anson Ho for setting up the database;
544	Julie Au and Lilly Wang for administrative support; Hetti Cheung, Victoria Wong, Bobo Yeung
545	at HKU Health System; Cindy Man and other colleagues at the HKU Community Vaccination
546	Centres at Gleneagles Hospital; and all the study participants for facilitating the study.
547	
548	Funding
549	This project was supported by the Health and Medical Research Fund (grant no. COVID19F09),
550	and the Theme-based Research Scheme of the Research Grants Council of the Hong Kong
551	Special Administrative Region, China (grant no. T11-705/21-N). BJC is supported by the
552	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department
553	of Health and Human Services, under contract no. 75N93021C00015, and a RGC Senior
554	Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the
555	Hong Kong Special Administrative Region, China. The funding bodies had no role in the design
556	of the study, the collection, analysis, and interpretation of data, or writing of the manuscript.
557	
558	Author contributions
559	All authors meet the ICMJE criteria for authorship. Each author's contributions to the paper are

- 560 listed below according to the CrediT model:
- 561 Conceptualization: NHLL, GML, BJC.
- 562 Methodology: NHLL, SMSC, CAC, JSMP, SAV, BJC.
- 563 Formal analysis: NHLL, CAC, MM-S, SAV, BJC.

- 564 Investigation: CAC, NYMA, LLHL, LCHT, KKHK, SC, LWCF, AWLC, KCKC, JKCL, YYN,
- 565 PK, JZJ.
- 566 Funding acquisition: NHLL, GML, BJC.
- 567 Project administration: NHLL, SMSC, JSMP, SAV, BJC.
- 568 Supervision: NHLL, SMSC, DKMI, LLMP, JSMP, SAV, BJC.
- 569 Writing original draft: NHLL, CAC, MM-S, JSMP, SAV, BJC.
- 570 Writing review & editing: NHLL, SMSC, CAC, MM-S, NYMA, LLHL, LCHT, KKHK, SC,
- 571 LWCF, AWLC, KCKC, JKCL, YYN, PK, JZJ, DKMI, LLMP, GML, JSMP, SAV, BJC.
- 572

573 Data availability	573	Data	availa	ability
-----------------------	-----	------	--------	---------

- 574 Data to reproduce the results shown here will be posted on github after peer review and
- 575 publication of our article.
- 576

### 577 Competing interests

- 578 BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and
- 579 Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no
- 580 other potential conflicts of interest.
- 581
- 582



584 Figure 1. Flow chart of participant enrolment for this open-label randomised trial of

585 CoronaVac or BNT162b2 provided as a third vaccine dose in adults who previously

586 received two doses of either vaccine. A more detailed flow chart with reasons for exclusion at

587 each stage is provided in Supplementary Figure S1.









598







- 628 percentages of IFNγ-producing cells from 0% to 100% with increments of 25%, and the position
- of measurement on line represents the mean value of the 20 participants. Tn: naïve T cells, Tcm:
- 630 central memory T cells, Tem: effector memory T cells, Teem: terminal effector memory T cells.



632

633 Figure 5. Cumulative incidence of SARS-CoV-2 infection after a randomised third dose of

634 CoronaVac or BNT162b2 vaccine, in adults who previously received two doses of (A)

635 CoronaVac or (B) BNT162b2, from after third-dose vaccination until 31 May 2022 and

636 during the period when the Omicron BA.2 subvariant was circulating. SARS-CoV-2

637 infections were identified by rapid antigen test or PCR. The four study arms included

638 participants who previously received two-dose CoronaVac and were randomised to receive a

639 third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously

640 received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-

641 C") or BNT162b2 ("BB-B").

- 642
- 643

### 644 **Table 1. Characteristics of all vaccinated participants at baseline.** We enrolled adults who

- 645 previously received two doses of CoronaVac or BNT162b2, and randomly assigned participants
- to receive either vaccine as a third dose, i.e. the four study arms included participants who
- 647 previously received two-dose CoronaVac and were randomised to receive a homologous third
- dose of CoronaVac ("CC-C") or a heterologous third dose of BNT162b2 ("CC-B"), and
- 649 participants who previously received two-dose BNT162b2 and were randomised to receive a
- 650 heterologous third dose of CoronaVac ("BB-C") or a homologous third dose of BNT162b2
- 651 ("BB-B"). Differences with p-values  $\leq 0.05$  were highlighted in bold.

		Received two doses of CoronaVac			Received two doses of BNT162b2		
	All enrolled	(CC)			(BB)		
Chamatanistia	and received						
Characteristic	third dose	Randomised to	Randomised to	) n_	Randomised to	Randomised to	) n_
		CoronaVac	BNT162b2	<b>Р-</b>	CoronaVac	BNT162b2	р- .b2
	vaccination	(CC-C)	(CC-B)	value	( <b>BB-C</b> )	(BB-B)	value
	(N = 451)	(N = 101)	(N = 118)		(N = 118)	(N = 114)	
	n (%)	n (%)	n (%)		n (%)	n (%)	
Female	221 (49)	47 (47)	64 (54)	0.13	51 (43)	59 (52)	0.5
Age (median, IQR)	54 (47-60)	58 (50-64)	52 (43-58)	0.01	56 (47-60)	53 (46-59)	0.55
Chinese	443 (98)	100 (99)	116 (98)	0.31	116 (98)	111 (97)	0.79
Obesity (for Asian							
populations)							
Underweight (BMI < 18.5)	23 (5)	6 (6)	6 (5)	0.97	4 (3)	7 (6)	0.6
Normal (BMI 18.5 – 22.9)	187 (41)	45 (45)	52 (44)		50 (42)	40 (35)	
Overweight (BMI 23.0 –	90 (22)	20 (20)	22 (10)		28 (24)	20 (25)	
24.9)	99 (22)	20 (20)	22 (19)		28 (24)	29 (23)	
Obese (BMI $\geq$ 25.0)	142 (31)	30 (30)	38 (32)		36 (31)	38 (33)	

#### **Chronic medical**

#### conditions

Any	104 (23)	21 (21)	21 (18)	>0.99	30 (25)	32 (28)	0.9
Lung disease, including COPD and asthma	3 (1)	2 (2)	0 (0)	0.5	0 (0)	1 (1)	>0.99
Heart disease	5 (1)	2 (2)	1 (1)	>0.99	2 (2)	0 (0)	0.5
Hypertension	45 (10)	9 (9)	10 (8)	>0.99	7 (6)	19 (17)	0.03
Diabetes	13 (3)	6 (6)	2 (2)	0.29	3 (3)	2 (2)	>0.99
Hypercholesterolemia	28 (6)	7 (7)	3 (3)	0.34	9 (8)	9 (8)	>0.99
Kidney disease	1 (0)	0 (0)	0 (0)	>0.99	1 (1)	0 (0)	>0.99
Liver disease	7 (2)	1 (1)	2 (2)	>0.99	2 (2)	2 (2)	>0.99
Cancer	6 (1)	3 (3)	2 (2)	>0.99	0 (0)	1 (1)	>0.99
Days between first and second dose of COVID-19 vaccination (median, IQR)	27 (21-28)	28 (28-29)	28 (28-29)	0.59	21 (21-23)	21 (21-24)	0.63
Days between second and third (study) dose of COVID-19 vaccination (median, IQR)	232 (200-247)	236 (211-245)	236 (214-247)	0.51	226 (195-246)	222 (196-249)	0.98
Smoking							
Ever	20 (4)	8 (8)	7 (6)	>0.99	2 (2)	3 (3)	>0.99
Current	11 (2)	4 (4)	5 (4)	>0.99	1 (1)	1 (1)	>0.99

652